Aldosterone and type 2 diabetes mellitus

References

1. Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245–50.10.1161/01.CIR.0000140677.20606.0ESearch in Google Scholar PubMed

2. Manrique C, Lastra G, Whaley-Connell A, Sowers JR. Hypertension and the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2005;7:471–6.10.1111/j.1524-6175.2005.04617.xSearch in Google Scholar PubMed PubMed Central

3. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875–80.10.1038/nature05487Search in Google Scholar PubMed

4. Sowers JR. Metabolic risk factors and renal disease. Kidney Int 2007;71:719–20.10.1038/sj.ki.5002006Search in Google Scholar PubMed

5. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, Stas S, Sowers JR. Renin-angiotensin aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007; 293:H2009–23.10.1152/ajpheart.00522.2007Search in Google Scholar PubMed

6. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002;970:89–100.10.1111/j.1749-6632.2002.tb04415.xSearch in Google Scholar PubMed

7. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006;47:312–18.10.1161/01.HYP.0000201443.63240.a7Search in Google Scholar PubMed

8. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006;47:693–700.10.1016/j.jacc.2005.09.050Search in Google Scholar PubMed

9. Neumann S, Huse K, Semrau R, Diegeler A, Gebhardt R, Buniatian GH, Scholz GH. Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 2002;39:756–60.10.1161/hy0302.105295Search in Google Scholar PubMed

10. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243–8.10.1016/j.jacc.2005.01.015Search in Google Scholar PubMed

11. Pearce D, Bhargava A, Cole TJ. Aldosterone: its receptor, target genes, and actions. Vitam Horm 2003;66:29–76.10.1016/S0083-6729(03)01002-1Search in Google Scholar

12. Verrey F, Pearce D, Pfeiffer R, Spindler B, Mastroberardino L, Summa V and Zecevic M. Pleiotropic action of aldosterone in epithelia mediated by transcription and post-transcription mechanisms. KidneyInt 2000;57:1277–82.10.1046/j.1523-1755.2000.00962.xSearch in Google Scholar

13. Wilson PW. and Meigs JB. Cardiometabolic risk: a Framingham perspective. Int J Obes (Lond.) 2008;32:S17–2.10.1038/ijo.2008.30Search in Google Scholar

14. Pujo L, Fagart J, Gary F, Papadimitriou DT, Claës A, Jeunemaître X, Zennaro MC. Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. Hum Mutat 2007;28:33–40.10.1002/humu.20371Search in Google Scholar

15. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001;104, 545–56.10.1016/S0092-8674(01)00241-0Search in Google Scholar

16. Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012;59:1069–78.10.1161/HYPERTENSIONAHA.111.190223Search in Google Scholar PubMed

17. Cooper JN, Fried L, Tepper P, Barinas-Mitchell E, Conroy MB, Evans RW, Mori Brooks M, Woodard GA, Sutton-Tyrrell K. Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults. Hypertens Res 2013;36:895–901.10.1038/hr.2013.45Search in Google Scholar PubMed PubMed Central

18. Shamiss A, Carroll J, Rosenthal T. Insulin resistance in secondary hypertension. Am J Hypertens 1992;10:755–9.10.1093/ajh/5.1.26Search in Google Scholar PubMed

19. Corry DB, Tuck M: The effect of aldosterone on glucose metabolism. Curr Hypertens Rep 2003;5:106–9.10.1007/s11906-003-0065-2Search in Google Scholar PubMed

20. Skrha J, Haas T, Šindelka G, Prazny M, Widimský JR, Cibula D, Svacina S: Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab 2004;89:135–41.10.1210/jc.2002-030024Search in Google Scholar PubMed

21. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity and primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006;91:3457–63.10.1210/jc.2006-0736Search in Google Scholar PubMed

22. Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, Boscaro M: Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007;25:177–86.10.1097/HJH.0b013e3280108e6fSearch in Google Scholar PubMed

23. McFarlane SI, Sowers JR. Cardiovascular endocrinology: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab 2003;88:516–23.10.1210/jc.2002-021443Search in Google Scholar PubMed

24. Swaminathan K, Davies J, George J, Rajendra NS, Morris AD, Struthers AD. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 2008;51:762–68.10.1007/s00125-008-0972-5Search in Google Scholar PubMed

25. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009;150:776–83.10.7326/0003-4819-150-11-200906020-00005Search in Google Scholar PubMed PubMed Central

26. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008;51:161–7.10.1161/HYPERTENSIONAHA.107.095489Search in Google Scholar PubMed

27. Wehling M, Christ M, Theisen K. Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action. Am J Physiol 1992;263:E974–9.10.1152/ajpendo.1992.263.5.E974Search in Google Scholar PubMed

28. Zennaro MC, Caprio M, Fève B. Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol Metab 2009;20:444–51.10.1016/j.tem.2009.05.006Search in Google Scholar PubMed

29. Caprio M, Fève B, Claës A, Viengchareun S, Lombès M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007;21:2185–94.10.1096/fj.06-7970comSearch in Google Scholar PubMed

30. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004;89:1045–50.10.1210/jc.2003-031337Search in Google Scholar PubMed

31. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective study of the prevalence of pa in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293–300.10.1016/j.jacc.2006.07.059Search in Google Scholar

32. Conn JW. Presidential address. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955;45:3–17.Search in Google Scholar

33. Abad-Cardiel M, Alvarez-Álvarez B, Luque-Fernandez L, Fernández C, Fernández-Cruz A, Martell-Claros N. Hypertension caused by primary hyperaldosteronism: increased heart damage and cardiovascular risk. Revista Española de Cardiología 2013;66:47–52.10.1016/j.rec.2012.07.017Search in Google Scholar

34. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266–81.10.1210/jc.2008-0104Search in Google Scholar

35. Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, Mantero F, Pessina AC. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of PA. Hypertension 2013;62:62–9.10.1161/HYPERTENSIONAHA.113.01316Search in Google Scholar

36. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486–97.10.1001/jama.285.19.2486Search in Google Scholar

37. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006;91:454–459.10.1210/jc.2005-1733Search in Google Scholar

38. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F; An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Diagnosis and management of the metabolic syndrome. Circulation 2005;112:2735–52.10.1161/CIRCULATIONAHA.105.169404Search in Google Scholar

39. Ivanes F, Susen S, Mouquet F, Pigny P, Cuilleret F, Sautière K, Collet JP, Beygui F, Hennache B, Ennezat PV, Juthier F, Richard F, Dallongeville J, Hillaert MA, Doevendans PA, Jude B, Bertrand M, Montalescot G, Van Belle E. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J 2012;33:191–202.10.1093/eurheartj/ehr176Search in Google Scholar

40. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2012;350:256–65.10.1016/j.mce.2011.06.014Search in Google Scholar

41. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253–9.10.1016/S0140-6736(99)12323-7Search in Google Scholar

42. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.10.1056/NEJMoa030207Search in Google Scholar PubMed

43. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709–717.10.1056/NEJM199909023411001Search in Google Scholar PubMed

44. O’Keefe JH, Abuissa H, Pitt B. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 2008;10:492–7.10.1111/j.1463-1326.2007.00730.xSearch in Google Scholar PubMed

45. Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008;118:2515–22.10.1161/CIRCULATIONAHA.108.772665Search in Google Scholar PubMed

46. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif J-C, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008;118:2506–25.10.1161/CIRCULATIONAHA.108.790733Search in Google Scholar PubMed

47. Joffe HV, Kwong RY, Gerhard-Herman MD, Rice C, Feldman K, Adler GK. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007;92:2552–8.10.1210/jc.2007-0393Search in Google Scholar PubMed

48. Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, Fardella CE. A possible association between PA and a lower beta-cell function. J Hyperten 2007;25:2125–30.10.1097/HJH.0b013e3282861fa4Search in Google Scholar PubMed

49. Luther JM. Effects of aldosterone on insulin sensitivity and secretion. Steroids 2014;91:54–60.10.1016/j.steroids.2014.08.016Search in Google Scholar PubMed PubMed Central

50. Sherajee SJ, Fujita Y, Rafiq K, Nakano D, Mori H, Masaki T, Hara T, Kohno M, Nishiyama A, Hitomi H. Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Arterioscler Thromb Vasc Biol 2012;32:257–63.10.1161/ATVBAHA.111.240697Search in Google Scholar PubMed

51. Levine TB, Levine AB. Metabolic syndrome and cardiovascular disease. 1st edition. Mishawaka, IN, USA: Saunders, 2006. Print.Search in Google Scholar

52. Chen W, Li F, He C, Zhu Y, Tan W. Elevated prevalence of abnormal glucose metabolism in patients with PA: a meta-analysis. Ir J Med Sci 2014;183:283–91.10.1007/s11845-013-1007-xSearch in Google Scholar PubMed

53. Giacchetti G, Sechi LA, Rilli S, Carey RM: The renin-angiotensin aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005;16:120–5.10.1016/j.tem.2005.02.003Search in Google Scholar PubMed

54. Bruder-Nascimento T, da Silva MAB, Tostes RC. The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes. Diabetol Metab Syndr 2014;6:90.10.1186/1758-5996-6-90Search in Google Scholar PubMed PubMed Central

55. Umpierrez GE, Cantey P, Smiley D, Palacio A, Temponi D, Luster K, Chapman A. PA in diabetic subjects with resistant hypertension. Diabetes Care 2007;30:1699–703.10.2337/dc07-0031Search in Google Scholar PubMed

56. Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vettor R, Veglio F, Mulatero P. Adiponectin and insulin sensitivity in PA. Am J Hypertens 2007;20:855–61.10.1016/j.amjhyper.2007.03.012Search in Google Scholar PubMed

57. Choi CS, Thompson CB, Leong PK, McDonough AA, Youn JH. Short-term K(+) deprivation provokes insulin resistance of cellular K(+) uptake revealed with the K(+) clamp. Am J Physiol Renal Physiol 2001;280:F95–102.10.1152/ajprenal.2001.280.1.F95Search in Google Scholar PubMed

58. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin Resistance and Hyperinsulinemia Are Related to Plasma Aldosterone Levels in Hypertensive Patients. Diabetes Care 2007;30:2349–54.10.2337/dc07-0525Search in Google Scholar PubMed

59. Fallo F, Dalla Pozza A, Tecchio M, Tona F, Sonino N, Ermani M, Catena C, Bertello C, Mulatero P, Sabato N, Fabris B, Sechi LA. Nonalcoholic fatty liver disease in PA: a pilot study. Am J Hypertens 2010;23:2–5.10.1038/ajh.2009.206Search in Google Scholar PubMed

60. Fischer E, Adolf C, Pallauf A, Then C, Bidlingmaier M, Beuschlein F, Seissler J, Reincke M. Aldosterone excess impairs first phase insulin secretion in PA. J Clin Endocrinol Metab 2013;98:2513–20.10.1210/jc.2012-3934Search in Google Scholar PubMed